Reviews of glioma immunotherapy identify both peptide vaccines (e.g., rindopepimut, IMA950, IDH1) and CAR-T cells as promising combination options that may overcome antigen escape and limited immune persistence [37,38]. Here, IDH1 is linked to glioma.